Castle Biosciences 미래 성장

Future 기준 확인 0/6

Castle Biosciences 의 수익은 연간 25.1% 감소할 것으로 예상되는 반면, 연간 수익은 3% 로 증가할 것으로 예상됩니다. 3% 연간. EPS는 연간 30.6% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -3.8% 로 예상됩니다.

주요 정보

-25.1%

수익 성장률

-30.6%

EPS 성장률

Healthcare 수익 성장	17.4%
매출 성장률	3.0%
향후 자기자본 수익률	-3.8%
애널리스트 커버리지	Good
마지막 업데이트	28 Jan 2025

최근 미래 성장 업데이트

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08

Recent updates

Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 12

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

수익 및 매출 성장 예측

NasdaqGM:CSTL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	325	-22	44	63	3
12/31/2026	297	-37	31	45	6
12/31/2025	269	-51	12	24	8
12/31/2024	330	11	38	64	4
9/30/2024	312	6	35	59	N/A
6/30/2024	288	-3	20	41	N/A
3/31/2024	251	-31	-6	13	N/A
12/31/2023	220	-57	-19	-6	N/A
9/30/2023	192	-76	-42	-30	N/A
6/30/2023	168	-89	-52	-40	N/A
3/31/2023	152	-72	-54	-46	N/A
12/31/2022	137	-67	-47	-42	N/A
9/30/2022	124	-53	-43	-38	N/A
6/30/2022	110	-44	-43	-39	N/A
3/31/2022	98	-52	-40	-37	N/A
12/31/2021	94	-31	-22	-19	N/A
9/30/2021	86	-30	-20	-17	N/A
6/30/2021	78	-23	-18	-13	N/A
3/31/2021	68	-15	1	6	N/A
12/31/2020	63	-10	5	10	N/A
9/30/2020	63	-3	10	15	N/A
6/30/2020	63	7	16	18	N/A
3/31/2020	61	6	4	5	N/A
12/31/2019	52	3	6	7	N/A
9/30/2019	46	4	-1	-1	N/A
6/30/2019	35	-6	-4	-3	N/A
3/31/2019	28	-8	-9	-8	N/A
12/31/2018	23	-10	-13	-12	N/A
12/31/2017	41	-46	N/A	-37	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CSTL 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -25.1% ).

수익 vs 시장: CSTL 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -25.1% ).

고성장 수익: CSTL 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: CSTL 의 수익(연간 3% ) US 시장( 8.8% 보다 느리게 성장할 것으로 예상됩니다. 8.8% 연간).

고성장 수익: CSTL 의 수익(연간 3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CSTL (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/31 20:39
장 마감 주가	2025/01/31 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Castle Biosciences, Inc. 9 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Catherine Ramsey Schulte	Baird
Mark Massaro	BTIG
Kyle Mikson	Canaccord Genuity

Castle Biosciences 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 28%

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Consensus estimates of losses per share improve by 26%

Recent updates

Castle Biosciences, Inc. Announces New York State Department of Health Approval of Its TissueCypher Barrett's Esophagus Test

Castle Biosciences, Inc. Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma

Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research

Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology

Castle Biosciences: Inflection Into Profitability

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test

Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology

Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM

Consensus estimates of losses per share improve by 28%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75